Rheumatology Advisor
Rheumtaology Advisor offers featured news, research updates, and treatment guidelines to Rheumatology healthcare professionals.
American College of Rheumatology Releases Updated Guidelines …
2021年6月18日 · The American College of Rheumatology (ACR) recently released updated guidelines for the pharmacologic management of rheumatoid arthritis (RA). The full report has been published simultaneously in Arthritis Care & Research and Arthritis & Rheumatology.. Overall, the updated guidelines include treatment with disease-modifying antirheumatic drugs (DMARDs), including biologic DMARDs (bDMARDs) and ...
Rheumatologists Discuss Management of Muscle Loss in …
2022年10月14日 · Muscle weakness — also known as rheumatoid cachexia or rheumatoid sarcopenia — is a common occurrence among patients with RA. Credit: Getty Images Rheumatologists, Joshua Baker, MD, Brian Andonian, MD, and Ira Khanna, MD, discuss the occurrence and management of muscle weakness and …
2022 ACR/AAHKS Guidelines for Management of
2022年4月6日 · References. American College of Rheumatology & American Association of Hip and Knee Surgeons. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip …
Serum CXCL13 Levels Show Potential as a Biomarker for Tailoring …
3 天之前 · High levels of serum C-X-C motif chemokine 13 (CXCL13) among patients with early rheumatoid arthritis (RA) are predictive of a reduced response to methotrexate (MTX), according to study findings published in Rheumatology (Oxford).. While MTX is a standard treatment for RA, many patients do not achieve an adequate response.
Upadacitinib Is Safe and Effective for Treating Rheumatoid Arthritis ...
2024年5月31日 · Upadacitinib is safe and effective for treating rheumatoid arthritis (RA) over 5 years, according to study results published in The Journal of Rheumatology.. The previously published SELECT-NEXT trial (ClinicalTrials.gov Identifier: NCT02675426) reported the safety and efficacy of upadacitinib up to 60 weeks, in terms of clinical and functional outcomes among patients with RA and an inadequate ...
Switch or Swap: Strategies for Anti-TNF Failure in Rheumatoid …
Rheumatoid arthritis (RA), a progressive and painful systemic inflammatory disease that preferentially attacks the synovium of the joint, affects approximately 1% of the adults around the world. 1 In the last several decades, the availability of targeted biological and synthetic disease-modifying antirheumatic drugs (DMARDs), along with …
Updated 2019 ACR Recommendations for Rheumatoid Arthritis …
2019年12月2日 · A working group of rheumatologists and rheumatology professionals convened to update the American College of Rheumatology (ACR) recommendations for rheumatoid arthritis (RA) disease activity measures by identifying 11 measures that met the minimum standard and 5 that were preferred for regular use in clinical settings, according to a systematic literature review published in Arthritis Care ...
Updated EULAR Recommendations for Rheumatoid Arthritis …
2020年2月13日 · Based on emerging new evidence and expert consensus, an international task force put together by the European League Against Rheumatism (EULAR) released updated recommendations for the management of rheumatoid arthritis (RA) with synthetic and biologic disease-modifying antirheumatic drugs (DMARDs).
Early Assessment and Biologics Improve Bone Health in …
2024年10月1日 · A significant decrease in the prevalence of osteoporosis and associated fractures among patients with rheumatoid arthritis (RA) was observed over a 24-year period, with early osteological assessment and the use of biological disease-modifying antirheumatic drugs (bDMARDs) associated with better bone health outcomes, according to …